1. Home
  2. Analysis
  3. Optimark
  4. Pioglitazone

Optimark and Pioglitazone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Optimark (gadoversetamide) and Pioglitazone (pioglitazone hydrochloride). Common drug interactions include nephrogenic systemic fibrosis among females and anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Optimark and Pioglitazone. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Optimark?

Optimark has active ingredients of gadoversetamide. eHealthMe is studying from 3,055 Optimark users. Check the latest studies of Optimark.

What is Pioglitazone?

Pioglitazone has active ingredients of pioglitazone hydrochloride. It is often used in diabetes. eHealthMe is studying from 12,864 Pioglitazone users. Check the latest studies of Pioglitazone.

On Jul, 10, 2026

13 people who take Optimark and Pioglitazone together, and have interactions are studied.

Optimark and Pioglitazone drug interactions.

What are the common drug interactions of Optimark and Pioglitazone, by gender? *:

female:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Deformity (disfigurement)
  3. Erythema (redness of the skin)
  4. General physical health deterioration (weak health status)
  5. Hypoaesthesia (reduced sense of touch or sensation)
  6. Oedema peripheral (superficial swelling)
  7. Pain
  8. Pain in extremity
  9. Scar
  10. Skin lesion

male:

  1. Anxiety
  2. Bone pain
  3. Emotional distress
  4. General physical health deterioration (weak health status)
  5. Injury
  6. Mobility decreased (ability to move is reduced)
  7. Muscular weakness (muscle weakness)
  8. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  9. Pain
  10. Renal failure chronic (long lasting kidney dysfunction)

What are the common drug interactions of Optimark and Pioglitazone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Deformity (disfigurement)
  3. Nausea (feeling of having an urge to vomit)
  4. Vomiting
  5. Erythema (redness of the skin)
  6. General physical health deterioration (weak health status)
  7. Hypoaesthesia (reduced sense of touch or sensation)
  8. Oedema peripheral (superficial swelling)
  9. Pain
  10. Pain in extremity

What are the existing conditions these people have? *

  1. Nuclear Magnetic Resonance Imaging Brain: 5 people, 38.46%
  2. Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Optimark and Pioglitazone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Optimark and Pioglitazone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Optimark:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pioglitazone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Optimark and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pioglitazone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gadoversetamide and pioglitazone hydrochloride (the active ingredients of Optimark and Pioglitazone, respectively), and Optimark and Pioglitazone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.